Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 15/20 | 0.47 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PTGFR | P43088 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12540033 | 0.87 | MAP2K1 (0.51) | MAP2K1MAP2K2 | |
| SCHEMBL2049340 | 0.77 | MAP2K1 (0.37) | MAP2K1 | |
| SCHEMBL5555415 | 0.73 | MAP2K1 (0.54) | MAP2K1MAP2K2 | |
| SCHEMBL12540063 | 0.71 | MAP2K1 (0.41) | MAP2K1MAP2K2 | |
| SCHEMBL27883682 | 0.69 | MAP2K1 (0.56) | MAP2K1MAP2K2 | |
| SCHEMBL12540057 | 0.68 | MAP2K1 (0.38) | MAP2K1MAP2K2ABCB11NQO2NPC1 | |
| SCHEMBL12540056 | 0.68 | MAP2K1 (0.43) | MAP2K1MAP2K2ABCB11NQO2DYRK1A | |
| SCHEMBL30185614 | 0.68 | MAP2K1 (0.71) | MAP2K1MAP2K2 | |
| SCHEMBL1344228 | 0.67 | MAP2K1 (0.45) | MAP2K1MAP2K2ABCB11NQO2NPC1 | |
| SCHEMBL4344176 | 0.66 | MAP2K1 (0.41) | MAP2K1MAP2K2ABCB11NQO2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509964-B1 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2014-04-30 | — | — | EP | disclosed |
| US-8614239-B2 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2013-12-24 | — | — | US | disclosed |
| US-20120245209-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245209-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | BRAF, NRAS, MAP3K1 | MAP2K1 103/4885MAP2K2 77/4885ABCB11 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.